Zymeworks
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline f...
Latest News
21 hours ago · globenewswire.com
Zymeworks Announces $200 Million Share Repurchase AuthorizationZymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and expected contribution to Total Shareholder Return (TSR) Zymeworks intends to balance capital allocation for 2027 thoughtfully across disciplined R&D pipeline development, selective M&A transactions and opportunistic share repurchases to grow underlying enterprise value while returning capital to shareholders through reducing share count over time VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a second 2026 share repurchase program under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share. Zymeworks completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to $125.0 million of its outstanding common stock.
7 days ago · zacks.com
Zymeworks Inc. (ZYME) Misses Q3 Earnings EstimatesZymeworks Inc. (ZYME) came out with quarterly earnings of $2.28 per share, missing the Zacks Consensus Estimate of $2.4 per share. This compares to a loss of $0.26 per share a year ago.
7 days ago · globenewswire.com
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsVANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2026 and provided a summary of recent business highlights. The Company has elected not to host a third quarter earnings conference call after release of its financial results.
19 days ago · zacks.com
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthZymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
20 days ago · marketbeat.com
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal UpsideZymeworks NASDAQ: ZYME outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its recently announced collaboration with Roche for the DLL3-targeting T-cell engager ZW209.
20 days ago · seekingalpha.com
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates TranscriptZymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
24 days ago · globenewswire.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
25 days ago · globenewswire.com
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a T cell engager targeting DLL3.
29 days ago · globenewswire.com
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaVANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, Ms. Monahan will lead Zymeworks' commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease (COPD), following the Company's recent acquisition of Theravance Biopharma.
1 month ago · globenewswire.com
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsZymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ZYME